BE333357A - - Google Patents
Info
- Publication number
- BE333357A BE333357A BE333357DA BE333357A BE 333357 A BE333357 A BE 333357A BE 333357D A BE333357D A BE 333357DA BE 333357 A BE333357 A BE 333357A
- Authority
- BE
- Belgium
- Prior art keywords
- water
- solutions
- dissolved
- desc
- parts
- Prior art date
Links
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 10
- 239000003814 drug Substances 0.000 claims description 6
- 229940079593 drugs Drugs 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 5
- 150000002170 ethers Chemical class 0.000 claims description 3
- 150000001298 alcohols Chemical class 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 150000002148 esters Chemical class 0.000 claims description 2
- 238000000034 method Methods 0.000 claims description 2
- 239000000243 solution Substances 0.000 description 11
- 239000002904 solvent Substances 0.000 description 11
- WIHIUTUAHOZVLE-UHFFFAOYSA-N 1,3-diethoxypropan-2-ol Chemical compound CCOCC(O)COCC WIHIUTUAHOZVLE-UHFFFAOYSA-N 0.000 description 6
- DSSYKIVIOFKYAU-UHFFFAOYSA-N Camphor Chemical compound C1CC2(C)C(=O)CC1C2(C)C DSSYKIVIOFKYAU-UHFFFAOYSA-N 0.000 description 4
- 241000723346 Cinnamomum camphora Species 0.000 description 4
- 229960000846 Camphor Drugs 0.000 description 3
- 229930007890 camphor Natural products 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- ZNQVEEAIQZEUHB-UHFFFAOYSA-N 2-Ethoxyethanol Chemical compound CCOCCO ZNQVEEAIQZEUHB-UHFFFAOYSA-N 0.000 description 2
- 210000002966 Serum Anatomy 0.000 description 2
- 230000002349 favourable Effects 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 230000000147 hypnotic Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 210000001519 tissues Anatomy 0.000 description 2
- UORJNBVJVRLXMQ-UHFFFAOYSA-N Aprobarbital Chemical compound C=CCC1(C(C)C)C(=O)NC(=O)NC1=O UORJNBVJVRLXMQ-UHFFFAOYSA-N 0.000 description 1
- 239000004348 Glyceryl diacetate Substances 0.000 description 1
- 241000209149 Zea Species 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 229960003153 aprobarbital Drugs 0.000 description 1
- JXLHNMVSKXFWAO-UHFFFAOYSA-N azane;7-fluoro-2,1,3-benzoxadiazole-4-sulfonic acid Chemical compound N.OS(=O)(=O)C1=CC=C(F)C2=NON=C12 JXLHNMVSKXFWAO-UHFFFAOYSA-N 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 230000001413 cellular Effects 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 235000005824 corn Nutrition 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N ethyl acetate Substances CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 1
- 239000010685 fatty oil Substances 0.000 description 1
- 235000019443 glyceryl diacetate Nutrition 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000003326 hypnotic agent Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 230000000607 poisoning Effects 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Description
<Desc/Clms Page number 1>
"Procédé -pour la -préparation de solutions d e médicaments"
La présenté invention a pour objet la préparation de solu- tions de médicaments.
Nous avons trouvé que les éthers etles esters d'alcools polyvalents qui sont solfies dans l'eau , par exemple les éthers de la glycérine et du glycol, tels que la diéthyline, l'éther glycolmonoéthylique ou l'ester mono-ou di-acétique de la glycé- rine, possèdent à un haut degré la propriété de dissoudre les médicaments. En comparaison avec d'autres dissolvants employés dans le but en question les nouveaux dissolvants présentent 1' avantage que leur action proportionnelle de distribution est au- tant favorable pour les huiles que pour les médiums aqueux et qu'en conséquence ils se dissolvent dans les lipoides cellulaires et dans le sérum.
A cause des dites propriétés les nouveaux dissolvants ont pris une grande importance dans la thérapeutique médicinale. Si' l'on se sert par exemple des solutions de camphre en une huile grasse, telles qu'on emploie dans le traitement d'affections
<Desc/Clms Page number 2>
cardiaques, le médicament ne passe que lentement de l'endroit ' d'injection dans la .circulation du sang, ce qui est dû à la solu- bilité inférieure des dissolvants employés jusqu'à présent dans les humeurs des tissus et dans le sérum du corps humain. Par contre , les solutions de camphre dans les nouveaux dissolvants se résorbent rapidement dans l'organisme humain à cause de la dite action de distribution favorable .
On peut cependant employer aussi les nouveaux dissolvants dans d'autres domaines de la thérapeutique avec les mêmes bons résultats tant pour l'application per os que pour application parentérale. Ainsi on n'a encore connu aucun dissolvant pour les hypnotiques qui d'un côté dissout l'hypnotique en'concentra -tion suffisante et qui de l'autre côté , est de caractère in- différent de sorte qu'on peut les injecter sans causer par cela une irritation du tissu ou des intoxications*
En outre , en injectant certains agents thérapeutiques ba- siques on a constaté que la sulibilité difficile de ces agents présente de grands inconvénients, les bases respectives étant insolubles dans l'eau tandis que les sels sont souvent extrême- ment difficilement solubles- Dans certaines circonstances les sels, quand on les dissout dans l'eau ,
se dissocient même en une base et en un acide un faitqui exclut naturellement l'em -ploi des substances en question pour des injections. Cependant à l'aide de nos nouveaux dissolvants il est possible de préparer facilement des solutions suffisamment concentrées des bases.Ces solutions, si elles ne sont pas trop concentrées, sont générale -ment susceptibles d'être diluées à volonté avec de l'eau, sans qu'il y ait précipitation de la base. Les nouveaux dissolvants, qu'ils soient dilués ou non avec de l'eau , permettent aussi d'améliorer très souvent la solubilité des sels des bases en question.
@
Les nouveaux dissolvants présentent l'avantage ultérieur qu'ils permettent par exemple la préparation de solutions de plusieurs substances qu'on veut dissoudre simultanément. Dans ce
<Desc/Clms Page number 3>
cas il peut arriver que /un des composants est très facilement soluble dans l'eau tandis' que l'autre y est très difficilement soluble .L'emploi de telles préparations combinées pour des in -jections sous-cutanées et intraveineuses est impraticable.
Par contre , en se servant des, dissolvants nouveaux on réussit fa- cilement à préparer des solutions qui sont susceptibles d'être injectées telles quelles ou diluées avec de l'eau ou d'être ad- ministrées per os en potions* Exemples.- 1) On dissout 10 parties en poids de camphre japonais dans 90 parties de diéthyline. La solution se présente sous for- me d'un liquide limpide claire
3) On dissout 20 parties en poids de camphre racémi- que synthétique dans 80'parties de diéthyline. On obtient ainsi une solution limpide de couleur claire .
3) On dissout une partie en poids de diéthylallyla- oétamide (voir brevet allemand ? 412 820) dans 8 parties de diéthyline. Le liquide ainsi obtenu est clair et limpide.
4) On fait digérer une partie en'poids de diéthylal- lylacétamide avec 2 parties d'éther glycolmonoêthylique. La dissolution seproduit très rapidement.
5) On dissout une partie en poids d'acide allyliso- propylbarb'iturique dans 6 parties de diéthyline en chauffant doucement-
EMI3.1
6) On dissout 0,5 grammes de .9-diamino-'-thoxya- cridine (voir brevet allemand N 364.037) dans 10 corn. de diéthy -line en chauffant-
7) On dissout 5 grammes de phlorophénylacétophénone (voir brevet allemand N 407 666) dans 45 grammes de diacétine.
8) On dissout 20 grammes d'un mélange composé de
EMI3.2
quantités moléculaires de,- phényidiméthylpyrazolonméthylamino'-' méthane'sulfonate' de sodium qui est facilement soluble dans l'eat (voir brevet belge N 296 160) et de dimèthylaminophényld1mé- thylpyrazoldn qui est difficilement soluble dans l'eau, dans un mélange de 20 grammes de diéthyline et 60 grammes d' eau.
<Desc/Clms Page number 4>
On peut stériliser . chaud les solutions produites d'a- près les exemples précédents et les rendre ainsi stables à perpétuité.
EMI4.1
R'lD IGAT T 01T.
**ATTENTION** fin du champ DESC peut contenir debut de CLMS **.
<Desc / Clms Page number 1>
"Process -for the -preparation of drug solutions"
The present invention relates to the preparation of drug solutions.
We have found that ethers and esters of polyvalent alcohols which are soluble in water, for example the ethers of glycerin and of glycol, such as diethylin, glycol monoethyl ether or mono-or di-acetic ester of glycerin, possess to a high degree the property of dissolving drugs. In comparison with other solvents employed for the purpose in question the new solvents have the advantage that their proportional distributing action is as favorable for oils as for aqueous mediums and therefore they dissolve in lipoids. cellular and in serum.
Because of these properties new solvents have gained great importance in medicinal therapy. If, for example, one uses solutions of camphor in a fatty oil, as employed in the treatment of ailments
<Desc / Clms Page number 2>
cardiac conditions, the drug passes only slowly from the injection site into the blood circulation, which is due to the inferior solubility of the solvents heretofore employed in tissue humors and in blood serum. human body. On the other hand, the solutions of camphor in the new solvents are rapidly reabsorbed in the human organism because of the said favorable distribution action.
However, the new solvents can also be used in other fields of therapy with the same good results for both oral and parenteral application. Thus no solvent has yet been known for hypnotics which on the one hand dissolves the hypnotic in sufficient concentration and which, on the other hand, is of an indistinguishable character so that they can be injected without thereby causing tissue irritation or poisoning *
In addition, by injecting certain basic therapeutic agents it has been found that the difficult sulibility of these agents presents great drawbacks, the respective bases being insoluble in water while the salts are often extremely poorly soluble. salts, when dissolved in water,
even dissociate into a base and an acid a fact which naturally excludes the use of the substances in question for injections. However, with the help of our new solvents it is possible to easily prepare sufficiently concentrated solutions of the bases. These solutions, if they are not too concentrated, are generally capable of being diluted at will with water, without any precipitation from the base. The new solvents, whether or not diluted with water, also very often make it possible to improve the solubility of the salts of the bases in question.
@
The new solvents have the further advantage that they allow, for example, the preparation of solutions of several substances which one wishes to dissolve simultaneously. In this
<Desc / Clms Page number 3>
In this case it may happen that one of the components is very easily soluble in water while the other is very hardly soluble in it. The use of such combined preparations for subcutaneous and intravenous injections is impractical.
On the other hand, by using new solvents, it is easy to prepare solutions which can be injected as they are or diluted with water or be administered orally in potions. 1) 10 parts by weight of Japanese camphor are dissolved in 90 parts of diethylin. The solution is presented as a clear, limpid liquid.
3) 20 parts by weight of synthetic racemic camphor are dissolved in 80 parts of diethylin. A clear, light-colored solution is thus obtained.
3) One part by weight of diethylallyloetamide (see German Patent No. 412,820) is dissolved in 8 parts of diethylin. The liquid thus obtained is clear and limpid.
4) One part by weight of diethylalylacetamide is digested with 2 parts of glycol monoethyl ether. Dissolution occurs very quickly.
5) One part by weight of allylisopropylbarbituric acid is dissolved in 6 parts of diethylin with gentle heating.
EMI3.1
6) 0.5 grams of 9-diamino -'-thoxyacridine (see German Patent No. 364,037) is dissolved in 10 corn. of diethy -line while heating-
7) 5 grams of phlorophenylacetophenone (see German Patent No. 407 666) are dissolved in 45 grams of diacetin.
8) 20 grams of a mixture composed of
EMI3.2
molecular quantities of, - sodium phenyidimethylpyrazolonmethylamino'- 'methane'sulphonate' which is easily soluble in ae (see Belgian patent N 296 160) and of dimethylaminophényld1methylpyrazoldn which is hardly soluble in water, in a mixture of 20 grams of diethylin and 60 grams of water.
<Desc / Clms Page number 4>
We can sterilize. hot the solutions produced according to the preceding examples and thus make them stable in perpetuity.
EMI4.1
R'lD IGAT T 01T.
** ATTENTION ** end of DESC field can contain start of CLMS **.
Claims (1)
Publications (1)
Publication Number | Publication Date |
---|---|
BE333357A true BE333357A (en) |
Family
ID=12141
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BE333357D BE333357A (en) |
Country Status (1)
Country | Link |
---|---|
BE (1) | BE333357A (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2381522A1 (en) * | 1977-02-26 | 1978-09-22 | Basf Ag | Drug solutions in 1-propyl 1,2-propylene glycol ether - which are stable and sterilisable for prepn. of injectable compsns. |
-
0
- BE BE333357D patent/BE333357A/fr unknown
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2381522A1 (en) * | 1977-02-26 | 1978-09-22 | Basf Ag | Drug solutions in 1-propyl 1,2-propylene glycol ether - which are stable and sterilisable for prepn. of injectable compsns. |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0173729B1 (en) | Process for solubilizing active principles and pharmaceutical compositions thus obtained | |
ES2764991T3 (en) | Solid formulations of biologically active liquid agents | |
ES2711760T3 (en) | Oil / water emulsions comprising semifluorinated alkanes | |
JP5616228B2 (en) | Topical composition | |
US8460644B2 (en) | Synergistic mixed poloxamer systems for the solubilisation of drugs | |
RU2250101C2 (en) | Anesthetizing formulas | |
HU224318B1 (en) | Composition and method for treating penile erectile dysfunction | |
PT98790B (en) | Process for the preparation of a pharmaceutical composition comprising FLORPHENICOL | |
KR20010039671A (en) | Anesthetic composition for intravenous injection comprising propofol | |
WO2011012816A2 (en) | Pharmaceutical formulation | |
EA035079B1 (en) | Diclofenac composition | |
BE333357A (en) | ||
EP1002531B1 (en) | A water-miscible composition of nimesulide | |
PL218606B1 (en) | Injectable veterinary composition for small animals | |
WO2009007660A1 (en) | Liquid or paste compositions intended to provide elements essential for the synthesis and formation of proteoglycans, in particular, for the treatment of cartilage degradation | |
US20090221496A1 (en) | novel antithrombotic agent | |
JPH0466847B2 (en) | ||
ES2328814T3 (en) | TERIAL EUTECTIC MIXTURES OF LOCAL ANESTHETICS. | |
Galletly et al. | Diazepam mixed micelle—comparison with diazepam in propylene glycol and midazolam | |
RU2366423C1 (en) | Oncotherapeutic preparation of 5-fluorouracil | |
RU2445097C1 (en) | Method for treating female genital cancer with 5-fluorouracil and metronidazole | |
US7645765B2 (en) | Use of moxaverin for treating erectile dysfunction, forms of dementia or diseases associated to an arteriosclerotic occlusion | |
BR102022004449A2 (en) | MICROEMULSION PHARMACEUTICAL FORMULATION FOR TREATMENT OF CUTANEOUS LEISHMANIASIS | |
KR100357449B1 (en) | A parenteral water-miscible non-intensely coloured injectable composition of non-steroidal anti-inflammatory drugs | |
US1752305A (en) | Solution of medicament and process of preparing same |